EGFR and head and neck cancer: Based on the synergistic effects seen in preclinical studies between green tea PPE and EGFR-tyrosine kinase inhibitors [334], a 6-month phase IB study of PPE (200 mg three times a day) and erlotinib (dose escalation of erlotinib (50, 75, and 100 mg daily)) was conducted in patients with head and neck cancer who had advanced premalignant lesions (APL) of the oral cavity and larynx.